HCA Healthcare (HCA) Stock Forecast & Price Target

$461.78 +3.18 (+0.69%)

As of 02:50 PM Eastern

Compare

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
1

Hold
7

Buy
16

Based on 24 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 1 has given a sell rating, 7 have given a hold rating, and 16 have given a buy rating for HCA.

Consensus Price Target

$467.61
1.26% Upside

According to the 24 analysts' twelve-month price targets for HCA Healthcare, the average price target is $467.61. The highest price target for HCA is $579.00, while the lowest price target for HCA is $380.00. The average price target represents a forecasted upside of 1.26% from the current price of $461.78.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HCA Analyst Ratings Over Time

Type	Current Forecast 10/13/25 to 10/13/26	1 Month Ago 9/13/25 to 9/13/26	3 Months Ago 7/15/25 to 7/15/26	1 Year Ago 10/13/24 to 10/13/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	16 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	8 Buy rating(s)
Hold	7 Hold rating(s)	8 Hold rating(s)	9 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$467.61	$462.64	$491.77	$422.31
Forecasted Upside	1.26% Upside	8.22% Upside	29.42% Upside	2.82% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

HCA Healthcare Stock vs. The Competition

Type	HCA Healthcare	Healthcare Companies	Broader Market
Consensus Rating Score	2.63	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	1.47% Upside	1,063.17% Upside	19.56% Upside
News Sentiment Rating	Neutral News See Recent HCA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/12/2026	TD Cowen 3 of 5 stars	Ryan Langston Not Rated	Boost Target	Buy	$431.00 ➝ $460.00	+1.31%
10/8/2026	Weiss Ratings 3 of 5 stars		Upgrade	Hold (C+) ➝ Buy (B-)
10/7/2026	Royal Bank Of Canada 3 of 5 stars	Ben Hendrix 3 of 5 stars	Boost Target	Outperform	$435.00 ➝ $496.00	+13.82%
10/2/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Sarah James Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Overweight
9/22/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Sean Dodge Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Market Perform ➝ Outperform	$495.00	+12.98%
9/18/2026	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Whit Mayo Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform	$492.00	+14.29%
8/20/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Benjamin Rossi Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Neutral	$490.00 ➝ $425.00	+4.83%
8/3/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Stephen Baxter Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Equal Weight	$369.00 ➝ $381.00	-7.87%
7/28/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Scott Fidel Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$558.00 ➝ $485.00	+24.44%
7/28/2026	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Ann Hynes Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$525.00 ➝ $475.00	+21.88%
Get the Latest News and Ratings for HCA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for HCA Healthcare and its competitors with MarketBeat's FREE daily newsletter.
7/27/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	A.J. Rice Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$635.00 ➝ $579.00	+49.09%
7/27/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$476.00	+22.57%
7/27/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Craig Hettenbach Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Underweight	$425.00 ➝ $380.00	-2.15%
7/27/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	David MacDonald Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$535.00 ➝ $495.00	+27.98%
7/27/2026	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Wiederhorn Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$520.00 ➝ $485.00	+26.30%
7/27/2026	KeyCorp Subscribe to MarketBeat All Access to unlock brokerage rankings	Matthew Gillmor Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$475.00 ➝ $435.00	+13.79%
7/27/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Andrew Mok Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Equal Weight	$402.00 ➝ $387.00	+1.23%
7/27/2026	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Michael Ha Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Neutral	$396.00 ➝ $393.00	+2.80%
7/15/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Lance Wilkes Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Market Perform
7/14/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$450.00	+23.47%
7/7/2026	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Sarah James Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$528.00	+23.26%
5/4/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Buy	$560.00 ➝ $500.00	+15.88%
4/27/2026	Stephens Subscribe to MarketBeat All Access to unlock brokerage rankings	Raj Kumar Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$560.00 ➝ $530.00	+19.56%
11/27/2025	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Strong-Buy ➝ Hold
10/27/2025	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Joanna Gajuk Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$430.00 ➝ $470.00	+1.71%
7/28/2025	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Justin Lake Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Outperform ➝ Peer Perform
4/9/2025	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Jason Cassorla Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:51 PM ET.

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 12, 2026. Please send any questions or comments about these HCA Healthcare pros and cons to contact@marketbeat.com.

HCA Healthcare
Bull Case

Here are some ways that investors could benefit from investing in HCA Healthcare, Inc.:

The stock is currently trading at $458.69, which is below the average analyst price target of $466.35, suggesting potential for upside as the consensus rating remains a Moderate Buy.
HCA Healthcare, Inc. recently reported Q2 2026 earnings of $7.59 per share, beating the consensus estimate of $7.56, while revenue of $20.23 billion exceeded expectations and grew 8.7% year-over-year.
The company maintains a consistent dividend policy, having recently paid a quarterly dividend of $0.78 per share, which annualizes to $3.12 and provides a yield of approximately 0.7% for income-focused investors.
Institutional interest remains strong, with 62.73% of the company's stock owned by institutional investors, indicating broad confidence in the long-term stability of the healthcare provider.
HCA Healthcare, Inc. is expanding its outpatient footprint, with recent reports highlighting a strategic goal to add 150 ambulatory surgery centers and 20 sites per hospital by 2030, positioning the company to capture growth in lower-cost care settings.

HCA Healthcare
Bear Case

Investors should be bearish about investing in HCA Healthcare, Inc. for these reasons:

The stock has experienced significant volatility, trading down from a 52-week high of $556.52 to the current price of $458.69, reflecting a substantial drawdown that may signal underlying market concerns.
Legal risks are present, as Pomerantz LLP is currently investigating claims on behalf of investors of HCA Healthcare, Inc., which could lead to potential liabilities or reputational damage.
Operational challenges are emerging, with reports indicating that HCA nurses have raised questions over an AI-enabled scheduling tool, suggesting potential friction in workforce management and technology adoption.
Insider selling activity has been notable, with several executives, including Michael R. McAlevey and Jennifer Berres, selling thousands of shares in early 2026, which may indicate a lack of confidence in near-term stock performance.
The company is facing escalating payment disputes with insurers, as HCA hospitals have intensified their fight over reimbursement rates, which could impact future revenue margins and cash flow stability.

HCA Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $467.61, with a high forecast of $579.00 and a low forecast of $380.00.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last year. There is currently 1 sell rating, 7 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCA shares.

According to analysts, HCA Healthcare's stock has a predicted upside of 1.26% based on their 12-month stock forecasts.

Over the previous 90 days, HCA Healthcare's stock had 1 upgrade by analysts.

HCA Healthcare has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., KeyCorp, Leerink Partners, Mizuho, Morgan Stanley, Oppenheimer, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like HCA Healthcare more than other "healthcare" companies. The consensus rating for HCA Healthcare is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how HCA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With HCA Healthcare Recommendations

MarketBeat monitors more than a dozen sources for HCA Healthcare analyst ratings, with the most recent rating issued on 10/12/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HCA Analyst Ratings Over Time

HCA Analyst Recommendations By Month

HCA Price Targets by Month

HCA Healthcare Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

HCA Healthcare
Bull Case

HCA Healthcare
Bear Case

HCA Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With HCA Healthcare Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

HCA Analyst Ratings Over Time

HCA Analyst Recommendations By Month

HCA Price Targets by Month

HCA Healthcare Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy HCA Healthcare Stock? HCA Pros and Cons Explained

HCA Healthcare Bull Case

HCA Healthcare Bear Case

HCA Forecast - Frequently Asked Questions

What is HCA Healthcare's forecast for 2026?

Should I buy or sell HCA Healthcare stock right now?

Does HCA Healthcare's stock price have much upside?

Has HCA Healthcare been upgraded by Wall Street analysts recently?

What analysts cover HCA Healthcare?

Do Wall Street analysts like HCA Healthcare more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With HCA Healthcare Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

HCA Healthcare
Bull Case

HCA Healthcare
Bear Case